Zahng Yuxue, Lan Jieying, Ma Xinyi, Zhou Qiong, Qin Mengchen, Gao Lei
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
the First Clinical School of Medicine, Southern Medical University, Guangzhou 510515, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Dec 20;44(12):2265-2275. doi: 10.12122/j.issn.1673-4254.2024.12.01.
To investigate the therapeutic effect of Exocarpium Citri Grandis formula granules (ECGFG) on fatty liver disease (FLD) in zebrafish and explore the underlying mechanism.
Nonalcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (ALD) models were established in zebrafish larvae at 3 days post fertilization (dpf), in which the treatment efficacy of 16, 32, or 64 μg/mL ECGFG was evaluated by examining zebrafish survival and liver pathologies and using whole-fish oil red O staining and RT-qPCR. The therapeutic mechanism of ECGFG for FLD was investigated using Prussian blue staining, DCFH-DA probe, MDA content detection, RT-qPCR assay and immunohistochemical staining for CAV1.
In zebrafish models of NAFLD and ALD, treatment with ECGFG significantly reduced lipid accumulation and the expression levels of FASN, SREBP1, HMGCRA, TNF-α and IL-6, increased the expressions of Apoa1 and PPARα, and reduced iron deposition and the contents of MDA and ROS in the liver. In zebrafish models of NAFLD, treatment with ECGFG at the 3 doses significantly increased hepatic expressions of Tf, TfR, FPN and SLC7A11, and at the doses of 32 and 64 μg/mL, ECGFG obviously increased hepatic expression of GPX4. ALD fish models showed significantly increased hepatic expressions of Tf, TfR and FPN, which were effectively lowered by treatment with ECGFG at the 3 doses. ECGFG did not obviously affect the expression of SLC7A11, but its high dose (64 μg/mL) caused significant elevation of GPX4 expression. Both zebrafish models of NAFLD and ALD showed obviously increased CAV1 expression level in the liver, which was significantly reduced by treatment with 32 and 64 μg/mL ECGFG.
In zebrafish models of NAFLD and ALD, ECGFG can alleviate lipid accumulation and inflammatory response and lower the expression level of CAV1 to restore iron homeostasis and suppress lipid peroxidation and ferroptosis in the liver.
研究化橘红配方颗粒(ECGFG)对斑马鱼脂肪肝疾病(FLD)的治疗效果,并探讨其潜在机制。
在受精后3天(dpf)的斑马鱼幼体中建立非酒精性脂肪肝(NAFLD)和酒精性脂肪肝(ALD)模型,通过检测斑马鱼存活率和肝脏病理变化,并使用全鱼油红O染色和RT-qPCR评估16、32或64μg/mL ECGFG的治疗效果。使用普鲁士蓝染色、DCFH-DA探针、MDA含量检测、RT-qPCR分析和CAV1免疫组化染色研究ECGFG治疗FLD的机制。
在NAFLD和ALD斑马鱼模型中,ECGFG治疗显著降低脂质积累以及FASN、SREBP1、HMGCRA、TNF-α和IL-6的表达水平,增加Apoa1和PPARα的表达,并减少肝脏中的铁沉积以及MDA和ROS的含量。在NAFLD斑马鱼模型中,3种剂量的ECGFG治疗均显著增加肝脏中Tf、TfR、FPN和SLC7A11的表达,在32和64μg/mL剂量下,ECGFG明显增加肝脏中GPX4的表达。ALD鱼类模型显示肝脏中Tf、TfR和FPN的表达显著增加,3种剂量的ECGFG治疗有效降低了这些表达。ECGFG对SLC7A11的表达没有明显影响,但其高剂量(64μg/mL)导致GPX4表达显著升高。NAFLD和ALD斑马鱼模型的肝脏中CAV1表达水平均明显升高,32和64μg/mL ECGFG治疗显著降低了该水平。
在NAFLD和ALD斑马鱼模型中,ECGFG可减轻脂质积累和炎症反应,降低CAV1表达水平,以恢复铁稳态,抑制肝脏脂质过氧化和铁死亡。